Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07004582 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

Study acronym: PR3DICT
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date changed from estimate of Feb 10, 2026 to Mar 15, 2026 · Site details revised at 3 of 3 sitesv3 Show 2 more changesShow less
    • Start date changed from estimate of Feb 10, 2026 to Mar 15, 2026
    • Site details revised at 3 of 3 sites
  2. Start date: Oct 1, 2025 to Feb 10, 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer. In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.
Trial Details
NCT Number NCT07004582
Lead Sponsor Maastricht Radiation Oncology
Collaborators: Zuyderland Medical Centre, Maastricht University Medical Center
Conditions Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Advanced Prostate Cancer
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov